Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
J Biomed Sci
; 30(1): 89, 2023 Oct 21.
Article
em En
| MEDLINE
| ID: mdl-37864230
ABSTRACT
Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR T-cell associated HLH (carHLH), and discuss their pathophysiology, symptoms, grading, and diagnosis systems, as well as management. In a future outlook, we also provide an overview of measures and modifications to CAR-T cells that are currently being explored to limit toxicity.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Hematológicas
/
Síndromes Neurotóxicas
/
Receptores de Antígenos Quiméricos
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article